Malignant Solid NeoplasmPhase 1NCT03997370
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
A Phase 1 study testing Biospecimen Collection, Carboplatin and Iohexol in people with Malignant Solid Neoplasm, run by NRG Oncology at 189 sites in 2 countries.
Trial summary
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Malignant Solid Neoplasm
- What is being tested?
- Biospecimen Collection, Carboplatin and Iohexol
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 350 participants
- Where
- 189 sitesin 2 countries
- Study dates
- 15 Jan 2020to 14 Mar 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
- For men who are sexually active, the need for use of medically acceptable contraception will be dictated by the primary treatment plan/protocol
- Study accrual was closed to women on 08/18/2021 and accrual is now only open to males in order to meet accrual goals and study objectives. (11-AUG-2021)
- Male sex
- Any patients who will receive treatment with intravenous carboplatin (any AUC, any cycle) on a National Cancer Institute (NCI)-sponsored National Clinical Trial Network (NCTN)-, Experimental Therapeutics Clinical Trials Network (ETCTN)-, trial, local trial, or through standard of care
- Age >= 18
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
Who cannot join
- Treated at an institute where creatinine is not measured with an IDMS calibrated assay
- History of allergic reactions to computed tomography (CT) contrast, iodine or shellfish, or history of anaphylactic reaction to any food item
- Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or have current indwelling nephrostomy tubes
- Edema beyond trace edema, because this will impact iohexol equilibration and distribution
- Ascites (including pleural effusion) beyond trace ascites, because this will impact iohexol equilibration and distribution
- Whole- or part-limb amputees, because this will impact iohexol equilibration and distribution
Show all 9Show fewer
- Inability to maintain a constant dose and schedule of anti-inflammatory agents, diuretics, angiotensin II receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi) for one week prior to study visit, as this impacts renal function. If the patient is on a nonsteroidal anti-inflammatory drug (NSAID), diuretic, ARB or ACEi, they are eligible as long as these agents are taken on a set schedule for 7 or more days prior to study (and not on an "as needed" basis as that can cause fluctuations in renal function)
- Inadequate venous access to obtain pharmacokinetic (PK) specimens
- Multinodular goiter, Graves' disease or autoimmune thyroiditis, per iohexol package insert (hypothyroidism is allowed)
Trial locations and contacts
189 sites in 2 countries.
189 sites in 2 countries
United States179 sites
OSF Saint Anthony's Health Center
Alton, Illinois, 62002
Community Hospital of Anaconda
Anaconda, Montana, 59711
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, 50023
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
Saint Alphonsus Cancer Care Center-Baker City
Baker City, Oregon, 97814
Mercy Oncology and Hematology - Clayton-Clarkson
Ballwin, Missouri, 63011
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Hematology/Oncology Clinic PLLC
Baton Rouge, Louisiana, 70809
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
Clara Maass Medical Center
Belleville, New Jersey, 07109
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Saint Elizabeth Boardman Hospital
Boardman, Ohio, 44512
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715
Cox Cancer Center Branson
Branson, Missouri, 65616
Roswell Park Cancer Institute
Buffalo, New York, 14263
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Mercy Cancer Center - Cape Girardeau
Cape Girardeau, Missouri, 63703
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Saint Mary's Hospital
Centralia, Illinois, 62801
Jefferson Cherry Hill Hospital
Cherry Hill, New Jersey, 08002
Memorial Hospital of Laramie County
Cheyenne, Wyoming, 82001
Northwestern University
Chicago, Illinois, 60611
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa, 50325
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Memorial Sloan Kettering Commack
Commack, New York, 11725
Carle at The Riverfront
Danville, Illinois, 61832
Miami Valley Hospital
Dayton, Ohio, 45409
Dayton Physician LLC - Englewood
Dayton, Ohio, 45415
Miami Valley Hospital North
Dayton, Ohio, 45415
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Broadlawns Medical Center
Des Moines, Iowa, 50314
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
The Cancer Institute at Saint Francis Hospital
East Hills, New York, 11548
Saint Elizabeth Healthcare Edgewood
Edgewood, Kentucky, 41017
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
Elizabeth, New Jersey, 07207
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Walter Knox Memorial Hospital
Emmett, Idaho, 83617
UC San Diego Health System - Encinitas
Encinitas, California, 92024
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
Armes Family Cancer Center
Findlay, Ohio, 45840
Blanchard Valley Hospital
Findlay, Ohio, 45840
Orion Cancer Care
Findlay, Ohio, 45840
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, 80528
UI Healthcare Mission Cancer and Blood - Fort Dodge
Fort Dodge, Iowa, 50501
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Vanderbilt-Ingram Cancer Center at Franklin
Franklin, Tennessee, 37067
Vanderbilt-Ingram Cancer Center Cool Springs
Franklin, Tennessee, 37067
Central Care Cancer Center - Garden City
Garden City, Kansas, 67846
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Central Care Cancer Center - Great Bend
Great Bend, Kansas, 67530
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
UCHealth Greeley Hospital
Greeley, Colorado, 80631
Dayton Physicians LLC-Wayne
Greenville, Ohio, 45331
Miami Valley Cancer Care and Infusion
Greenville, Ohio, 45331
Wayne Hospital
Greenville, Ohio, 45331
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Hartford Hospital
Hartford, Connecticut, 06102
Hi-Line Sletten Cancer Center
Havre, Montana, 59501
Benefis Helena Specialty Center
Helena, Montana, 59601
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Freeman Health System
Joplin, Missouri, 64804
Mercy Hospital Joplin
Joplin, Missouri, 64804
Logan Health Medical Center
Kalispell, Montana, 59901
Greater Dayton Cancer Center
Kettering, Ohio, 45409
First Dayton Cancer Care
Kettering, Ohio, 45420
Kettering Medical Center
Kettering, Ohio, 45429
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89106
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756
CARTI Cancer Center
Little Rock, Arkansas, 72205
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Cooperman Barnabas Medical Center
Livingston, New Jersey, 07039
Monmouth Medical Center
Long Branch, New Jersey, 07740
Medical Center of the Rockies
Loveland, Colorado, 80538
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Idaho Urologic Institute-Meridian
Meridian, Idaho, 83642
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Community Medical Center
Missoula, Montana, 59804
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
Monongalia Hospital
Morgantown, West Virginia, 26505
SSM Health Good Samaritan
Mount Vernon, Illinois, 62864
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, 83687
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
The Hospital of Central Connecticut
New Britain, Connecticut, 06050
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, 60451
Tulane University School of Medicine
New Orleans, Louisiana, 70112
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Rutgers New Jersey Medical School
Newark, New Jersey, 07101
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
Carle BroMenn Medical Center
Normal, Illinois, 61761
Carle Cancer Institute Normal
Normal, Illinois, 61761
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Saint Alphonsus Cancer Care Center-Ontario
Ontario, Oregon, 97914
University of Chicago Medicine-Orland Park
Orland Park, Illinois, 60462
Lake Regional Hospital
Osage Beach, Missouri, 65065
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Mercy Hospital Pittsburg
Pittsburg, Kansas, 66762
West Penn Hospital
Pittsburgh, Pennsylvania, 15224
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, 83854
Women and Infants Hospital
Providence, Rhode Island, 02905
Reid Health
Richmond, Indiana, 47374
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298
Highland Hospital
Rochester, New York, 14620
University of Rochester
Rochester, New York, 14642
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Phelps Health Delbert Day Cancer Institute
Rolla, Missouri, 65401
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
University of Utah Sugarhouse Health Center
Salt Lake City, Utah, 84106
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, 83864
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Sidney Kimmel Cancer Center Washington Township
Sewell, New Jersey, 08080
Welch Cancer Center
Sheridan, Wyoming, 82801
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey, 08876
Baystate Medical Center
Springfield, Massachusetts, 01199
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Springfield Regional Cancer Center
Springfield, Ohio, 45504
Springfield Regional Medical Center
Springfield, Ohio, 45504
Mercy Infusion Center - Chippewa
St Louis, Missouri, 63109
Mercy Hospital South
St Louis, Missouri, 63128
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
State University of New York Upstate Medical University
Syracuse, New York, 13210
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467
Community Medical Center
Toms River, New Jersey, 08755
Dayton Physicians LLC - Troy
Troy, Ohio, 45373
Upper Valley Medical Center
Troy, Ohio, 45373
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, 85704
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Carle Cancer Center
Urbana, Illinois, 61801
The Carle Foundation Hospital
Urbana, Illinois, 61801
Saint Joseph Warren Hospital
Warren, Ohio, 44484
Mercy Hospital Washington
Washington, Missouri, 63090
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016
UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa, 50263
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Good Samaritan University Hospital
West Islip, New York, 11795
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, 19090
Saint Elizabeth Youngstown Hospital
Youngstown, Ohio, 44501
Puerto Rico10 sites
Cancer Center-Metro Medical Center Bayamon
Bayamón, 00959-5060
Puerto Rico Hematology Oncology Group
Bayamón, 00961
HIMA San Pablo Oncologic Hospital
Caguas, 00726
Doctors Cancer Center
Manati, 00674
Instituto Oncologia Moderna Ponce
Ponce, 00716
San Juan Community Oncology Group
San Juan, 00917
Primary Care Physician Group
San Juan, 00920
Centro Comprensivo de Cancer de UPR
San Juan, 00927
PROncology
San Juan, 00927
San Juan City Hospital
San Juan, 00936
About this study
Official title: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Read the detailed description
PRIMARY OBJECTIVES:
- Evaluate the success of targeting a carboplatin area under the curve (AUC) with our current approach to dosing carboplatin.
II. Assess the performance of Cockcroft-Gault (CG), four-variable Modification of Diet in Renal Disease (MDRD-4), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) based on isotope dilution mass spectrometry (IDMS) calibrated serum creatinine in predicting measured glomerular filtration rate (mGFR) in patients with cancer.
III. Define the relationship of mGFR and carboplatin clearance in patients with cancer.
SECONDARY OBJECTIVES:
- Evaluate the divergence of estimated (e)GFR from mGFR based on patient demographic and other characteristics, thus identifying those most likely to benefit from determination of mGFR over use of eGFR.
II. Determine the success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped.
III. Evaluate the relationship between carboplatin exposure and toxicity. IV. Assess the ability of markers other than creatinine in pre-treatment serum to better estimate kidney function in patients with cancer.
OUTLINE:
Patients receive iohexol intravenously (IV) over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
After completion of study, patients are followed up for 3-4 weeks.
- Conditions
- Malignant Solid Neoplasm
- Being tested
- Biospecimen Collection, Carboplatin, Iohexol
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo collection of blood samples
CarboplatinDrug
Also called Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino
Given IV
IohexolDrug
Also called Omnipaque
Given IV
| Study group | Role | What they receive |
|---|---|---|
| Treatment (iohexol, standard care carboplatin, blood samples) | Experimental | Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis. Receives: Procedure: Biospecimen Collection; Drug: Carboplatin; Drug: Iohexol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy of achieving the targeted carboplatin area under the curve (AUC)
Will be quantified by the median percentage error (PE), root-mean-squared error (RMSE), interquartile range (IQR) of the residuals, and median absolute percentage error (APE). In addition, the percentage of patients for which the observed carboplatin AUC is within 17% of target will be calculated. The actual AUC will be quantified using atomic absorption spectrophotometry.
Measured: Up to 4 weeks
Precision of achieving the targeted carboplatin AUC
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE. In addition, the percentage of patients for which the observed carboplatin AUC is within 17% of target will be calculated. The actual AUC will be quantified using atomic absorption spectrophotometry.
Measured: Up to 4 weeks
Bias of the formula for estimated glomerular filtration rate (eGFR) currently in existence in patients with cancer
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE will be used to assess the accuracy of each model's eGFR values for predicting measured (m)GFR. In addition, will calculate the percentage of patients for which eGFR is within 30%, 20%, and 10% of mGFR.
Measured: Up to 4 weeks
Precision of the formula for eGFR currently in existence in patients with cancer
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE will be used to assess the accuracy of each model's eGFR values for predicting mGFR. In addition, will calculate the percentage of patients for which eGFR is within 30%, 20%, and 10% of mGFR.
Measured: Up to 4 weeks
Correlation between carboplatin clearance (CL) and mGFR
Assessed by regression analysis. Carboplatin clearance will be derived by Empirical Bayes estimation using the POSTHOC option implemented in NONMEM. Will perform regression on the relationship between CL and mGFR. Initially this will follow a linear relationship analogous to the Calvert formula (CL = A + B* mGFR), and will test if the observed values for A and B are significantly different from those defined by Calvert as A = 25 mL/min and B = 1 (unitless). Will also perform regression by other means, e.g. after log transformation of the data, and assess if this results in a formula that performs better than the Calvert formula or the initial linear model. In addition, the impact of covariates on this relationship will be explored.
Measured: Up to 4 weeks
Secondary outcomes (4)
Divergence of eGFR from mGFR
The bias of eGFR versus mGFR will be modeled as a function of the patient's characteristics.
Measured: Up to 4 weeks
Success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped
Among patients with eGFR > 125 mL/min, precision and bias will be estimated relative to the target carboplatin AUC.
Measured: Up to 4 weeks
Relationship between carboplatin exposure and toxicity
Will be described by the regression parameters for the estimated relationship between carboplatin AUC and platelet count, neutrophil count, and non-hematologic grade 3 toxicities.
Measured: Up to 4 weeks
Ability of markers in addition to creatinine in pre-treatment serum to better estimate kidney function in patients with cancer
These markers will include (but are not limited to) cystatin C, beta-2-microglobulin (B2M), and beta-trace-protein (BTP). Will use these markers and patient covariates (e.g. sex, race, weight etc.) as predictors for mGFR in regression efforts.
Measured: Up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2019
- Study start15 Jan 2020
- Primary completion14 Mar 2028 (estimated)
- Study completion14 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Solid NeoplasmStudies of the same condition, open and under way.
- More trials run by NRG OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 350 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NRG Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Sarah E Taylor, Principal investigator, NRG Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03997370
- Sponsor's protocol ID
- NRG-GY022
- Other IDs
- NCI-2019-04008, NRG-GY022, NRG-GY022, U10CA180868
- Status last verified
- Aug 2026
- First submitted
- 24 Jun 2019
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
- ClinicalTrials.gov ID
- NCT03997370
- Acronym / sponsor ID
- NRG-GY022
- Conditions
- Malignant Solid Neoplasm
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 350 participants (estimated)
- Lead sponsor
- NRG OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 15 Jan 2020 (actual)
- Primary completion
- 14 Mar 2028 (estimated)
- Study completion
- 14 Mar 2028 (estimated)
- First posted
- 25 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Detailed description
PRIMARY OBJECTIVES:
- Evaluate the success of targeting a carboplatin area under the curve (AUC) with our current approach to dosing carboplatin.
II. Assess the performance of Cockcroft-Gault (CG), four-variable Modification of Diet in Renal Disease (MDRD-4), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) based on isotope dilution mass spectrometry (IDMS) calibrated serum creatinine in predicting measured glomerular filtration rate (mGFR) in patients with cancer.
III. Define the relationship of mGFR and carboplatin clearance in patients with cancer.
SECONDARY OBJECTIVES:
- Evaluate the divergence of estimated (e)GFR from mGFR based on patient demographic and other characteristics, thus identifying those most likely to benefit from determination of mGFR over use of eGFR.
II. Determine the success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped.
III. Evaluate the relationship between carboplatin exposure and toxicity. IV. Assess the ability of markers other than creatinine in pre-treatment serum to better estimate kidney function in patients with cancer.
OUTLINE:
Patients receive iohexol intravenously (IV) over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
After completion of study, patients are followed up for 3-4 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment (iohexol, standard care carboplatin, blood samples) | Experimental | Procedure: Biospecimen Collection, Drug: Carboplatin, Drug: IohexolPatients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
- For men who are sexually active, the need for use of medically acceptable contraception will be dictated by the primary treatment plan/protocol
- Male sex
- Any patients who will receive treatment with intravenous carboplatin (any AUC, any cycle) on a National Cancer Institute (NCI)-sponsored National Clinical Trial Network (NCTN)-, Experimental Therapeutics Clinical Trials Network (ETCTN)-, trial, local trial, or through standard of care
- Age >= 18
Key exclusion criteria (9 listed)
- Treated at an institute where creatinine is not measured with an IDMS calibrated assay
- History of allergic reactions to computed tomography (CT) contrast, iodine or shellfish, or history of anaphylactic reaction to any food item
- Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or have current indwelling nephrostomy tubes
- Edema beyond trace edema, because this will impact iohexol equilibration and distribution
- Ascites (including pleural effusion) beyond trace ascites, because this will impact iohexol equilibration and distribution
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen CollectionUndergo collection of blood samples | Procedure or surgery | Treatment (iohexol, standard care carboplatin, blood samples) |
| CarboplatinAlso: Blastocarb, Carboplat, Carboplatin Hexal, CarboplatinoGiven IV | Drug | Treatment (iohexol, standard care carboplatin, blood samples) |
| IohexolAlso: OmnipaqueGiven IV | Drug | Treatment (iohexol, standard care carboplatin, blood samples) |
Primary outcome
Accuracy of achieving the targeted carboplatin area under the curve (AUC)
Time frame: Up to 4 weeks
Will be quantified by the median percentage error (PE), root-mean-squared error (RMSE), interquartile range (IQR) of the residuals, and median absolute percentage error (APE). In addition, the percentage of patients for which the observed carboplatin AUC is within 17% of target will be calculated. The actual AUC will be quantified using atomic absorption spectrophotometry.
Precision of achieving the targeted carboplatin AUC
Time frame: Up to 4 weeks
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE. In addition, the percentage of patients for which the observed carboplatin AUC is within 17% of target will be calculated. The actual AUC will be quantified using atomic absorption spectrophotometry.
Bias of the formula for estimated glomerular filtration rate (eGFR) currently in existence in patients with cancer
Time frame: Up to 4 weeks
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE will be used to assess the accuracy of each model's eGFR values for predicting measured (m)GFR. In addition, will calculate the percentage of patients for which eGFR is within 30%, 20%, and 10% of mGFR.
Precision of the formula for eGFR currently in existence in patients with cancer
Time frame: Up to 4 weeks
Will be quantified by the median PE, RMSE, IQR of the residuals, and median APE will be used to assess the accuracy of each model's eGFR values for predicting mGFR. In addition, will calculate the percentage of patients for which eGFR is within 30%, 20%, and 10% of mGFR.
Correlation between carboplatin clearance (CL) and mGFR
Time frame: Up to 4 weeks
Assessed by regression analysis. Carboplatin clearance will be derived by Empirical Bayes estimation using the POSTHOC option implemented in NONMEM. Will perform regression on the relationship between CL and mGFR. Initially this will follow a linear relationship analogous to the Calvert formula (CL = A + B* mGFR), and will test if the observed values for A and B are significantly different from those defined by Calvert as A = 25 mL/min and B = 1 (unitless). Will also perform regression by other means, e.g. after log transformation of the data, and assess if this results in a formula that performs better than the Calvert formula or the initial linear model. In addition, the impact of covariates on this relationship will be explored.
4 secondary outcomes
Divergence of eGFR from mGFR
Time frame: Up to 4 weeks
Success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped
Time frame: Up to 4 weeks
Relationship between carboplatin exposure and toxicity
Time frame: Up to 4 weeks
Ability of markers in addition to creatinine in pre-treatment serum to better estimate kidney function in patients with cancer
Time frame: Up to 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
Related trials for Malignant Solid Neoplasm
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Recruiting
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah E Taylor principal investigator
NRG Oncology
189 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Biospecimen Collection, Carboplatin and Iohexol in people with Malignant Solid Neoplasm, run by NRG Oncology at 189 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 189 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy of achieving the targeted carboplatin area under the curve (AUC) (time frame: Up to 4 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.